Unexpectedly High Prevalence of Common Variable Immunodeficiency in Finland

Common variable immunodeficiency (CVID) is the most common primary immunodeficiency. Prevalence varies greatly between countries and studies. Most diagnostic criteria include hypogammaglobulinemia and impaired vaccine response. To evaluate the minimum prevalence as well as the clinical and immunolog...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 8; p. 1190
Main Authors:	Selenius, Jannica S, Martelius, Timi, Pikkarainen, Sampsa, Siitonen, Sanna, Mattila, Eero, Pietikäinen, Risto, Suomalainen, Pekka, Aalto, Arja H, Saarela, Janna, Einarsdottir, Elisabet, Järvinen, Asko, Färkkilä, Martti, Kere, Juha, Seppänen, Mikko
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 28-09-2017
Subjects:	common variable immunodeficiency hypogammaglobulinemia Immunology Medicin och hälsovetenskap prevalence primary antibody deficiency primary immunodeficiency secondary antibody deficiency secondary antibody deficiency primary immunodeficiency prevalence common variable immunodeficiency hypogammaglobulinemia primary antibody deficiency
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Common variable immunodeficiency (CVID) is the most common primary immunodeficiency. Prevalence varies greatly between countries and studies. Most diagnostic criteria include hypogammaglobulinemia and impaired vaccine response. To evaluate the minimum prevalence as well as the clinical and immunological phenotypes of CVID in Southern Finland. We performed a cross-sectional study to assess all adult CVID patients followed up in three hospital districts in Southern and South-Eastern Finland between April 2007 and August 2015. CVID diagnosis was based, with a minor modification, on the ESID/PAGID criteria for primary CVID. Antipolysaccharide responses to Pneumovax were defined as impaired only if 50% or more of the serotypes did not reach a level of 0.35 µg/mL after vaccination. We further characterized the patients' B cell phenotypes and complications associated with CVID. In total, 9 patients were excluded due to potential secondary causes before diagnosis. ESID/PAGID criteria were met by 132 patients (males 52%), of whom, 106 had "probable" and 26 "possible CVID." Based on the population statistics in the three hospital districts, the minimum adult prevalence per 100,000 inhabitants in Finland for all CVID ("probable CVID," respectively) patients was 6.9 (5.5). In the highest prevalence district (Helsinki and Uusimaa), the prevalence was 7.7 (6.1). CVID patients suffer from frequent complications. Ten patients died during follow-up. Of probable CVID patients, 73% had more than one clinical phenotype. Intriguingly, gradual B cell loss from peripheral blood during follow-up was seen in as many as 16% of "probable CVID" patients. Patients with possible CVID displayed somewhat milder clinical and laboratory phenotypes than probable CVID patients. We also confirm that large granular lymphocyte lymphoproliferation is a CVID-associated complication. The prevalence of CVID in Finland appears the highest recorded, likely reflecting the genetic isolation and potential founder effects in the Finnish population. Studies to discover potential gene variants responsible for the high prevalence in Finland thus seem warranted. Increased awareness of CVID among physicians would likely lead to earlier diagnosis and improved quality of care.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Isabelle Meyts, KU Leuven, Belgium; Mike Recher, University of Basel, Switzerland Edited by: Guzide Aksu, Ege University, Turkey Specialty section: This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2017.01190